TWSTTwist Bioscience Corporation
What is the market doing?
No clear lean: in an uptrend, but a crowded short (+20% of shares).
In an uptrend, above its rising 50- and 200-day averages. Price is +110% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How TWST is trading
Twist Bioscience Corporation is +473% over the past year while the S&P 500 is +18%: 455 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +110%
vs 200-day average · a clear uptrend
- RSI (14)
- 48
RSI (14) · neutral
- Below its 52-week high
- 22%
Below its 52-week high
Details›
- Last close2026-10-09
- $159.83
- 1 monthS&P 500 +2.7%
- +26%
- 1 yearS&P 500 +18%
- +473%
- 5 yearsS&P 500 +88%
- +40%
- vs 50-day average$142.25
- +12%
- 52-week high
- $204.94
- 52-week low
- $25.45
- Annualised volatility
- 72%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$21M
| Year | Return |
|---|---|
| 2026 (year to date) | +404% |
| 2025 | −32% |
| 2024 | +26% |
| 2023 | +55% |
| 2022 | −69% |
| 2021 | −45% |
| 2020 | +573% |
| 2019 | −9.1% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 8 | 6 of 8 | +7.8% |
| Feb | 8 | 3 of 8 | −3.4% |
| Mar | 8 | 3 of 8 | −6.0% |
| Apr | 8 | 4 of 8 | −3.7% |
| May | 8 | 6 of 8 | +8.7% |
| Jun | 8 | 8 of 8 | +23% |
| Jul | 8 | 5 of 8 | +9.1% |
| Aug | 8 | 2 of 8 | −0.05% |
| Sep | 8 | 4 of 8 | +1.7% |
| Oct | 8 | 3 of 8 | −3.6% |
| Nov | 8 | 5 of 8 | +21% |
| Dec | 8 | 2 of 8 | +2.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Diagnostics & Research
Ranks #20 of 21 by RyuScore